Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
复发性慢性淋巴细胞白血病患者接受 MRD 指导的伊布替尼联合维奈克拉治疗的长期随访:VISION/HO141 II 期试验
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024015180
Niemann, Carsten U; Dubois, Julie; Nasserinejad, Kazem; da Cunha-Bang, Caspar; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J; Mous, Rogier; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie F; Dobber, Johan A; Poulsen, Christian B; Razawy, Wida; Hollestein, René; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C; Ranti, Juha; Brieghel, Christian; Mattsson, Mattias; Bellido, Mar; Tran, Hoa T T; Kater, Arnon P; Levin, Mark-David